Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02406521 · ClinicalTrials.gov registry record · Phase 1
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02406521: Completed Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT02406521 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02406521, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This research study is comparing different drug combinations as a possible treatment for metastatic renal cell carcinoma (mRCC) and bone metastases. The names of the study interventions involved in this study are: * Combination of Radium-223 and Sorafenib * Combination of Radium-223 and Pazopanib
Interventions
- DRUG Sorafenib
- DRUG Pazopanib
- DRUG Radium-223
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 1 |
What the finished NCT02406521 record still lists
NCT02406521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 3 interventions - of which Sorafenib is the first listed.
NCT02406521 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02406521 about?
NCT02406521 is a clinical study titled "Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets". This research study is comparing different drug combinations as a possible treatment for metastatic renal cell carcinoma (mRCC) and bone metastases. The names of the study interventions involved in this study are: * Combination of Radium-223 and Sorafenib * Combination of Radium-223 and Pazopanib
What is the current status of trial NCT02406521?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-04. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT02406521?
The interventions under investigation include: Sorafenib (DRUG), Pazopanib (DRUG), Radium-223 (DRUG).
Who is sponsoring clinical trial NCT02406521?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02406521's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia